Literature DB >> 27194384

Presymptomatic ALS genetic counseling and testing: Experience and recommendations.

Michael Benatar1, Christine Stanislaw2, Eliana Reyes2, Sumaira Hussain2, Anne Cooley2, Maria Catalina Fernandez2, Danielle D Dauphin2, Sara-Claude Michon2, Peter M Andersen2, Joanne Wuu2.   

Abstract

Remarkable advances in our understanding of the genetic contributions to amyotrophic lateral sclerosis (ALS) have sparked discussion and debate about whether clinical genetic testing should routinely be offered to patients with ALS. A related, but distinct, question is whether presymptomatic genetic testing should be offered to family members who may be at risk for developing ALS. Existing guidelines for presymptomatic counseling and testing are mostly based on small number of individuals, clinical judgment, and experience from other neurodegenerative disorders. Over the course of the last 8 years, we have provided testing and 317 genetic counseling sessions (including predecision, pretest, posttest, and ad hoc counseling) to 161 first-degree family members participating in the Pre-Symptomatic Familial ALS Study (Pre-fALS), as well as testing and 75 posttest counseling sessions to 63 individuals with familial ALS. Based on this experience, and the real-world challenges we have had to overcome in the process, we recommend an updated set of guidelines for providing presymptomatic genetic counseling and testing to people at high genetic risk for developing ALS. These recommendations are especially timely and relevant given the growing interest in studying presymptomatic ALS.
© 2016 American Academy of Neurology.

Entities:  

Mesh:

Year:  2016        PMID: 27194384      PMCID: PMC4909562          DOI: 10.1212/WNL.0000000000002773

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  29 in total

1.  Recommendations for the predictive genetic test in Huntington's disease.

Authors:  R MacLeod; A Tibben; M Frontali; G Evers-Kiebooms; A Jones; A Martinez-Descales; R A Roos
Journal:  Clin Genet       Date:  2012-07-30       Impact factor: 4.438

2.  Complexities of Genetic Counseling for ALS: A Case of Two Siblings with Discordant Genetic Test Results.

Authors:  Paola Mandich; Vittorio Mantero; Simonetta Verdiani; Fabio Gotta; Claudia Caponnetto; Emilia Bellone; Giovanna Ferrandes; Paola Origone
Journal:  J Genet Couns       Date:  2015-04-07       Impact factor: 2.537

Review 3.  Presymptomatic studies in ALS: rationale, challenges, and approach.

Authors:  Michael Benatar; Joanne Wuu
Journal:  Neurology       Date:  2012-10-16       Impact factor: 9.910

4.  Hereditary spastic paraplegia caused by a mutation in the VCP gene.

Authors:  Susanne T de Bot; Helenius J Schelhaas; Erik-Jan Kamsteeg; Bart P C van de Warrenburg
Journal:  Brain       Date:  2012-09-18       Impact factor: 13.501

5.  EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force.

Authors:  Peter M Andersen; Sharon Abrahams; Gian D Borasio; Mamede de Carvalho; Adriano Chio; Philip Van Damme; Orla Hardiman; Katja Kollewe; Karen E Morrison; Susanne Petri; Pierre-Francois Pradat; Vincenzo Silani; Barbara Tomik; Maria Wasner; Markus Weber
Journal:  Eur J Neurol       Date:  2011-09-14       Impact factor: 6.089

6.  Four familial ALS pedigrees discordant for two SOD1 mutations: are all SOD1 mutations pathogenic?

Authors:  Ansgar Felbecker; William Camu; Paul N Valdmanis; Anne-Dorte Sperfeld; Stefan Waibel; Peter Steinbach; Guy A Rouleau; Albert C Ludolph; Peter M Andersen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-05       Impact factor: 10.154

Review 7.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

Authors:  D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

Review 8.  Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. EALSC Working Group.

Authors:  Peter Munch Andersen; Gian Domenico Borasio; Reinhard Dengler; Orla Hardiman; Katja Kollewe; Peter Nigel Leigh; Pierre-Francois Pradat; Vincenzo Silani; Barbara Tomik
Journal:  Amyotroph Lateral Scler       Date:  2007-08

9.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.

Authors:  D R Rosen; T Siddique; D Patterson; D A Figlewicz; P Sapp; A Hentati; D Donaldson; J Goto; J P O'Regan; H X Deng
Journal:  Nature       Date:  1993-03-04       Impact factor: 49.962

Review 10.  Amyotrophic lateral sclerosis: Problems and prospects.

Authors:  Jemeen Sreedharan; Robert H Brown
Journal:  Ann Neurol       Date:  2013-09       Impact factor: 10.422

View more
  16 in total

Review 1.  The imaging signature of C9orf72 hexanucleotide repeat expansions: implications for clinical trials and therapy development.

Authors:  Stacey Li Hi Shing; Mary Clare McKenna; We Fong Siah; Rangariroyashe H Chipika; Orla Hardiman; Peter Bede
Journal:  Brain Imaging Behav       Date:  2021-01-05       Impact factor: 3.978

2.  Use of Genetic Testing in Amyotrophic Lateral Sclerosis by Neurologists.

Authors:  Karissa C Arthur; Carly Doyle; Adriano Chiò; Bryan J Traynor
Journal:  JAMA Neurol       Date:  2017-01-01       Impact factor: 18.302

3.  Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results.

Authors:  Angela R Bradbury; Linda J Patrick-Miller; Brian L Egleston; Michael J Hall; Susan M Domchek; Mary B Daly; Pamela Ganschow; Generosa Grana; Olufunmilayo I Olopade; Dominique Fetzer; Amanda Brandt; Rachelle Chambers; Dana F Clark; Andrea Forman; Rikki Gaber; Cassandra Gulden; Janice Horte; Jessica M Long; Terra Lucas; Shreshtha Madaan; Kristin Mattie; Danielle McKenna; Susan Montgomery; Sarah Nielsen; Jacquelyn Powers; Kim Rainey; Christina Rybak; Michelle Savage; Christina Seelaus; Jessica Stoll; Jill E Stopfer; Xinxin Shirley Yao
Journal:  J Natl Cancer Inst       Date:  2018-09-01       Impact factor: 13.506

4.  The NGS technology for the identification of genes associated with the ALS. A systematic review.

Authors:  Valentina Pecoraro; Jessica Mandrioli; Chiara Carone; Adriano Chiò; Bryan J Traynor; Tommaso Trenti
Journal:  Eur J Clin Invest       Date:  2020-05-19       Impact factor: 5.722

5.  Genetics and ALS: Cause for Optimism.

Authors:  Roland Pochet
Journal:  Cerebrum       Date:  2017-05-01

Review 6.  Developing multidisciplinary clinics for neuromuscular care and research.

Authors:  Sabrina Paganoni; Katie Nicholson; Fawn Leigh; Kathryn Swoboda; David Chad; Kristin Drake; Kellen Haley; Merit Cudkowicz; James D Berry
Journal:  Muscle Nerve       Date:  2017-08-29       Impact factor: 3.217

Review 7.  Genetic testing in ALS: A survey of current practices.

Authors:  Alice Vajda; Russell L McLaughlin; Mark Heverin; Owen Thorpe; Sharon Abrahams; Ammar Al-Chalabi; Orla Hardiman
Journal:  Neurology       Date:  2017-02-03       Impact factor: 9.910

Review 8.  Maximizing the Survival of Amyotrophic Lateral Sclerosis Patients: Current Perspectives.

Authors:  Osama A Khairoalsindi; Ahmad R Abuzinadah
Journal:  Neurol Res Int       Date:  2018-08-12

Review 9.  Predictive Genetic Counseling for Neurodegenerative Diseases: Past, Present, and Future.

Authors:  Jill S Goldman
Journal:  Cold Spring Harb Perspect Med       Date:  2020-07-01       Impact factor: 5.159

10.  Actions of the antihistaminergic clemastine on presymptomatic SOD1-G93A mice ameliorate ALS disease progression.

Authors:  Savina Apolloni; Paola Fabbrizio; Susanna Amadio; Cinzia Volonté
Journal:  J Neuroinflammation       Date:  2016-08-22       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.